Oddo BHF Asset Management Sas acquired a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 13,629 shares of the medical equipment provider's stock, valued at approximately $1,110,000.
A number of other large investors have also added to or reduced their stakes in HOLX. Prentiss Smith & Co. Inc. grew its stake in Hologic by 0.3% in the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider's stock valued at $3,967,000 after acquiring an additional 130 shares during the period. Covestor Ltd lifted its position in shares of Hologic by 23.8% during the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider's stock worth $56,000 after acquiring an additional 133 shares in the last quarter. First Horizon Advisors Inc. increased its position in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after buying an additional 134 shares during the period. Empirical Finance LLC boosted its holdings in Hologic by 1.8% in the 3rd quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider's stock valued at $690,000 after purchasing an additional 147 shares during the period. Finally, Wedmont Private Capital grew its position in Hologic by 3.7% during the third quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider's stock worth $361,000 after buying an additional 162 shares in the last quarter. Institutional investors own 94.73% of the company's stock.
Hologic Stock Down 1.9 %
NASDAQ:HOLX traded down $1.44 during mid-day trading on Friday, hitting $73.65. 2,553,425 shares of the company's stock were exchanged, compared to its average volume of 1,626,827. Hologic, Inc. has a one year low of $70.24 and a one year high of $84.67. The company has a market cap of $16.71 billion, a PE ratio of 22.12, a P/E/G ratio of 2.38 and a beta of 0.96. The business has a fifty day moving average price of $79.32 and a 200 day moving average price of $78.59. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03.
Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same period in the prior year, the company posted $0.89 earnings per share. The company's quarterly revenue was up 4.5% on a year-over-year basis. Equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.
Insider Buying and Selling
In other news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 1.75% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on the company. Citigroup cut Hologic from a "buy" rating to a "neutral" rating and dropped their target price for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. BNP Paribas raised shares of Hologic to a "strong-buy" rating in a report on Tuesday, December 10th. Wolfe Research started coverage on shares of Hologic in a research note on Friday. They set a "peer perform" rating for the company. JPMorgan Chase & Co. raised their target price on Hologic from $92.00 to $94.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Finally, Raymond James boosted their price target on Hologic from $93.00 to $95.00 and gave the company an "outperform" rating in a report on Tuesday, November 5th. Six research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $89.50.
View Our Latest Stock Analysis on Hologic
Hologic Company Profile
(
Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
See Also
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.